FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Cooper

Research Profile

Disorders

Living Beings

HIV-1

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

CD4-Positive T-Lymphocytes

Geographic Areas

Co-author Network

Publications

TOP 3
Yin Xu; Sheilajen Alcantara; Michelle Bailey; David A Cooper; Jacques Corbeil; Robert De Rose; Jerome Estaquier; Anthony D Kelleher; Stephen J Kent; Kazuo Suzuki; Chris Weatherall; Kim Wilson; John J Zaunders
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques.
James B Gilmore; Anthony D Kelleher; David A Cooper; John M Murray
Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action.
Leia H Wren; Marjon Navis; Matthew S Parsons; Ivan Stratov; Janaki Amin; Amy W Chung; David A Cooper; Gamze Isitman; Anthony D Kelleher; Stephen J Kent
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Cooper (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Yin Xu; Sheilajen Alcantara; Michelle Bailey; David A Cooper; Jacques Corbeil; Robert De Rose; Jerome Estaquier; Anthony D Kelleher; Stephen J Kent; Kazuo Suzuki; Chris Weatherall; Kim Wilson; John J Zaunders
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques.
Journal of virology 2013;87(7):3760-73.
2013: James B Gilmore; Anthony D Kelleher; David A Cooper; John M Murray
Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action.
PLoS computational biology 2013;9(3):e1002971.
2013: Leia H Wren; Marjon Navis; Matthew S Parsons; Ivan Stratov; Janaki Amin; Amy W Chung; David A Cooper; Gamze Isitman; Anthony D Kelleher; Stephen J Kent
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection.
Immunology 2013;138(2):116-23.
2013: Karen Schneider; David P Wilson; Jonathan Anderson; David A Cooper; Sean Emery; Richard Kaplan; Chidi A Nwizu; Mark A Boyd
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
PloS one 2013;8(2):e54435.
2013: Amit C Achhra; Janaki Amin; David A Cooper; Andrew E Grulich; Anthony D Kelleher; Matthew G Law; Julie Yeung
Changes in metabolic, inflammatory and coagulation biomarkers after HIV seroconversion - the Health in Men (HIM) Biomarker Substudy.
Antiviral therapy 2013;18(3):355-9.
2012: Thanyawee Puthanakit; Kiat Ruxrungtham; Vonthanak Saphonn; William T Shearer; Tulathip Suwarnlerk; Sasiwimol Ubolyam; Ung Vibol; Mean Chhi Vun; Jurai Wongsawat; Jintanat Ananworanich; Kea Chettra; Theshinee Cheunyam; David A Cooper; Lawrence Fox; Rawiwan Hansudewechakul; Suparat Kanjanavanit; Stephen J Kerr; Pope Kosalaraksa; Matthew G Law; Wicharn Luesomboon; Lynne M Mofenson; Chaiwat Ngampiyaskul; Nicole Ngo-Giang-Huong; Robert Paul; Praphan Phanuphak
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial.
The Lancet infectious diseases 2012;12(12):933-41.
2012: Damien V Cordery; Sean Emery; Anthony D Kelleher; Allison Martin; Janaki Amin; David A Cooper
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
AIDS (London, England) 2012;26(18):2337-44.
2012: Mark A Boyd; David A Cooper
Optimisation of HIV care and service delivery: doing more with less.
Lancet 2012;380(9856):1860-6.
2012: Benjamin G Oliver; Michael Phillips; Patricia Price; David A Cooper; Julian H Elliott; Martyn A French
Tuberculosis after commencing antiretroviral therapy for HIV infection is associated with elevated CXCL9 and CXCL10 responses to Mycobacterium tuberculosis antigens.
Journal of acquired immune deficiency syndromes (1999) 2012;61(3):287-92.
2012: Amit C Achhra; Janaki Amin; Haitao Chu; David A Cooper; David Dunn; Sean Emery; Joseph A Kovacs; Lewis H Kuller; Matthew G Law; Caroline Sabin
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.
AIDS (London, England) 2012;26(13):1707-17.
2012: Dianne Carey; Kate Beileiter; Mark Bloch; Mark A Boyd; Sean Emery; Karen MacRae; Sarah L Pett; John E Ray; Handan Wand; David A Cooper
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Journal of acquired immune deficiency syndromes (1999) 2012;60(2):143-9.
2012: John M Murray; Kazuo Suzuki; John J Zaunders; Janaki Amin; Michelle Bailey; David Baker; Christoph Boesecke; David A Cooper; Sean Emery; Anthony D Kelleher; Kersten K Koelsch; Kristin McBride
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.
AIDS (London, England) 2012;26(5):543-50.
2012: Stephen J Kerr; M Layton; Praphan Phanuphak; O Putcharoen; Kiat Ruxrungtham; Sasiwimol Ubolyam; A Avihingsanon; Ploenchan Chetchotisakd; David A Cooper; Chris Duncombe
Assessing adherence in Thai patients taking combination antiretroviral therapy.
International journal of STD & AIDS 2012;23(3):160-5.
2012: Amanda Clarke; David A Cooper; Chris Duncombe; Adam Honeybrook; Jintanat Ananworanich; Anchalee Avihingsanon; Stephen Kerr; Praphan Phanuphak; Kiat Ruxrungtham; John Kaldor
Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in Bangkok.
The open virology journal 2012;6():23-8.
2012: Anchalee Avihingsanon; Scott Bowden; David A Cooper; Greg J Dore; Sharon R Lewin; Stephen Locarnini; Pip Marks; Gail V Matthews; Jose Sasadeusz; Kiat Ruxrungtham
Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand.
AIDS research and therapy 2012;9(1):6.
2012: Yu Ming Paul Lam; Kristin L McBride; Janaki Amin; David A Cooper; Damien V Cordery; Anthony D Kelleher; Kersten K Koelsch
Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
PloS one 2012;7(3):e31990.
2012: Sarah Sasson; Nabila Seddiki; Don E Smith; John J Zaunders; Michelle Bailey; David A Cooper; Kersten K Koelsch; Kristin McBride; Kate M Merlin; Anthony D Kelleher
Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection.
PloS one 2012;7(2):e31148.
2011: Damien V Cordery; David A Cooper
Optimal antiretroviral therapy for aging.
Sexual health 2011;8(4):534-40.
2011: Helen Byakwaga; David A Cooper; Sean Emery; Martyn A French; Roger Garsia; Hila Haskelberg; Anthony D Kelleher; Mark Kelly; Sharon R Lewin; Damian F J Purcell; Janaki Amin; Mark A Boyd
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
The Journal of infectious diseases 2011;204(10):1532-40.
2011: Kersten K Koelsch; Kristin McBride; John M Murray; Ven Natarajan; John J Zaunders; David Baker; Mark Bloch; Christoph Boesecke; David A Cooper; Sean Emery; Paul Fahey; Linda Gelgor; Anthony D Kelleher
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.
AIDS (London, England) 2011;25(17):2069-78.
2011: Kazuo Suzuki; Sanjay Swaminathan; Toshiki Watanabe; Makoto Yamagishi; Chantelle Ahlenstiel; Marina Alexander; Michael R Beard; David A Cooper; Takaomi Ishida; Katharine Marks; Erin M McCartney; Daniel Murray; Damian F J Purcell; Anthony D Kelleher
Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.
RNA biology 2011;8(6):1035-46.
2011: John M Murray; Anthony D Kelleher; David A Cooper
Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.
Journal of virology 2011;85(20):10798-805.
2011: Punnee Pitisuttithum; Supachai Rerks-Ngarm; Eric Sandstrom; Yiming Shao; Hiko Tamashiro; Michael W Benenson; Alan Bernstein; Joseph Chiu; David A Cooper; Rossana A Ditangco; Jose Esparza; Rajat Goyal; Rodney Hoff; Stephen J Kent; Jerome Kim; Amapola Manrique; Bonnie Mathieson; Saladin Osmanov
Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan).
The Southeast Asian journal of tropical medicine and public health 2011;42(5):1130-46.
2011: Stephen T Wright; Andrew Carr; David A Cooper; Michelle Giles; Jennifer Hoy; Matthew G Law; Ian Woolley
CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts.
Journal of acquired immune deficiency syndromes (1999) 2011;58(1):72-9.
2011: Leon P Botes; Fengyi Jin; Chris Bourne; Sarah Pett; Debbie Marriott; Andrew Carr; David A Cooper; Gail Matthews; Bruce J Brew; Richard J Hillman
Participants' perspectives of self-collected anal cytological swabs.
Sexual health 2011;8(2):257-8.
2011: Richard J Hillman; Sarah Pett; Debbie Marriott; Andrew Carr; David A Cooper; Gail V Matthews; Bruce J Brew; Sam Milliken; Leon P Botes
Participants' perspectives of high resolution anoscopy.
Sexual health 2011;8(2):255-6.
2011: S L Pett; C Carey; E Lin; D Wentworth; J Lazovski; J M Miró; F Gordin; B Angus; M Rodriguez-Barradas; R Rubio; G Tambussi; David A Cooper; Sean Emery
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).
HIV medicine 2011;12(4):219-27.
2011: Jintanat Ananworanich; S J Kerr; P Vernazza; S Mangclaviraj; S Chaithongwongwatthana; P Chotnopparatpattara; Apicha Mahanontharit; Sasiwimol Ubolyam; Thidarat Jupimai; David A Cooper; Kiat Ruxrungtham; Bernard Hirschel
Genital shedding of HIV after scheduled treatment interruption.
International journal of STD & AIDS 2011;22(2):61-6.
2011: Allison Martin; Janaki Amin; David Baker; Mark Bloch; Andrew Carr; David A Cooper; Sean Emery
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
PloS one 2011;6(10):e26885.
2011: Matthew G Law; Ian Woolley; David J Templeton; Norm Roth; John Chuah; Brian Mulhall; Peter Canavan; Hamish McManus; David A Cooper; Kathy Petoumenos
Trends in detectable viral load by calendar year in the Australian HIV observational database.
Journal of the International AIDS Society 2011;14():10.
2011: David J van Bockel; David A Price; Mee Ling Munier; Vanessa Venturi; Tedi E Asher; Kristin Ladell; Hui Yee Greenaway; John Zaunders; Daniel C Douek; David A Cooper; Miles P Davenport; Anthony D Kelleher
Persistent survival of prevalent clonotypes within an immunodominant HIV gag-specific CD8+ T cell response.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(1):359-71.
2011: Palanee Ammaranond; David J van Bockel; Kathy Petoumenos; Marylin McMurchie; Robert Finlayson; Melanie G Middleton; Miles P Davenport; Vanessa Venturi; Kazuo Suzuki; Linda Gelgor; John M Kaldor; David A Cooper; Anthony D Kelleher
HIV immune escape at an immunodominant epitope in HLA-B*27-positive individuals predicts viral load outcome.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(1):479-88.
2011: David A Cooper; Damien Cordery; P Reiss; K Henry; M Nelson; M O'Hearn; J Reynes; Keikawus Arastéh; J Chung; L Rowell; D Guimaraes; A Bertasso
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.
HIV medicine 2011;12(1):31-9.
2010: Benjamin G Oliver; Julian H Elliott; Patricia Price; Michael Phillips; Vonthanak Saphonn; Mean Chhi Vun; John M Kaldor; David A Cooper; Martyn A French
Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy.
The Journal of infectious diseases 2010;202(11):1728-37.
2010: Allison Martin; Janaki Amin; David A Cooper; Andrew Carr; Anthony D Kelleher; Mark Bloch; David Baker; Ian Woolley; Sean Emery
Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.
AIDS (London, England) 2010;24(17):2657-63.
2010: Rebekah L Puls; Preeyaporn Srasuebkul; Kathy Petoumenos; Christoph Boesecke; Chris Duncombe; Waldo H Belloso; Jean-Michel Molina; Lin Li; Anchalee Avihingsanon; Brian Gazzard; David A Cooper; Sean Emery
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;51(7):855-64.
2010: David A Cooper; Alex D Wodak; Brian J Morris
The case for boosting infant male circumcision in the face of rising heterosexual transmission of HIV.
The Medical journal of Australia 2010;193(6):318-9.
2010: Supachai Rerks-Ngarm; Punnee Pitisuttithum; Nirmal Ganguly; Linqi Zhang; Hiko Tamashiro; David A Cooper; Mean Chhi Vun; Budiman Bela; Rossana Ditangco; Nguyen Van Kinh; Alan Bernstein; Saladin Osmanov; Bonnie Mathieson; Stephen J Kent; Yiming Shao
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.
Current opinion in HIV and AIDS 2010;5(5):435-52.
2010: Stephen J Kent; David A Cooper; Mean Chhi Vun; Yiming Shao; Linqi Zhang; Nirmal Ganguly; Budiman Bela; Hiko Tamashiro; Rossana Ditangco; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Nguyen Van Kinh; Alan Bernstein; Saladin Osmanov
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines.
PLoS medicine 2010;7(9):e1000331.
2010: Alexandra Calmy; M Bloch; H Wand; C Delhumeau; R Finlayson; M Rafferty; R Norris; Bernard Hirschel; David A Cooper; Andrew Carr
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
HIV medicine 2010;11(8):493-501.
2010: Amit C Achhra; Janaki Amin; Matthew G Law; Sean Emery; Jan Gerstoft; Fred M Gordin; Michael J Vjecha; James D Neaton; David A Cooper
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.
AIDS (London, England) 2010;24(12):1877-86.
2010: Sarah Sasson; Sandy Smith; Nabila Seddiki; John J Zaunders; Adam Bryant; Kersten K Koelsch; Christopher Weatherall; Mee Ling Munier; Ciara McGinley; Julie Yeung; Stephen P Mulligan; John Moore; David A Cooper; Sam Milliken; Anthony D Kelleher
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers.
Cytokine 2010;50(1):58-68.
2010: David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin DeJesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna van der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
The Journal of infectious diseases 2010;201(6):803-13.
2010: Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah Puls; Kathy Petoumenos; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(6):920-9.
2010: Damien Cordery; David A Cooper
Clinical research in NSW: its role in HIV care and prevention.
New South Wales public health bulletin 2010;21(3-4):93-5.
2010: Roy T Steigbigel; David A Cooper; Hedy Teppler; Joseph J Eron; Jose M Gatell; Princy N Kumar; Jurgen K Rockstroh; Mauro Schechter; Christine Katlama; Martin Markowitz; Patrick Yeni; Mona R Loutfy; Adriano Lazzarin; Jeffrey Lennox; Bonaventura Clotet; Jing Zhao; Hong Wan; Rand R Rhodes; Kim M Strohmaier; Richard J Barnard; Robin D Isaacs; Bach-Yen Nguyen
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(4):605-12.
2010: Damien V Cordery; Karl Hesse; Janaki Amin; David A Cooper
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Antiviral therapy 2010;15(7):1035-8.
2010: Alexander Hoare; Stephen J Kerr; Kiat Ruxrungtham; Jintanat Ananworanich; Matthew G Law; David A Cooper; Praphan Phanuphak; David P Wilson
Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.
PloS one 2010;5(6):e10981.
2009: Alexandra Calmy; Christoph A Fux; Richard Norris; Nathalie Vallier; Cécile Delhumeau; Katherine Samaras; Karl Hesse; Bernard Hirschel; David A Cooper; Andrew Carr
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.
The Journal of infectious diseases 2009;200(11):1746-54.
2009: Julian H Elliott; Khol Vohith; Sarun Saramony; Chin Savuth; Chan Dara; Chel Sarim; Sarah Huffam; Robert Oelrichs; Pouv Sophea; Vonthanak Saphonn; John Kaldor; David A Cooper; Mean Chhi Vun; Martyn A French
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy.
The Journal of infectious diseases 2009;200(11):1736-45.
2009: Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(10):1591-601.
2009: Kersten K Koelsch; David A Cooper
Integrase inhibitors in salvage therapy regimens for HIV-1 infection.
Current opinion in HIV and AIDS 2009;4(6):518-23.
2009: John J Zaunders; Mee Ling Munier; Nabila Seddiki; Sarah Pett; Susanna Ip; Michelle Bailey; Yin Xu; Kai Brown; Wayne B Dyer; Min Kim; Robert De Rose; Stephen J Kent; Lele Jiang; Samuel N Breit; Sean Emery; Anthony L Cunningham; David A Cooper; Anthony D Kelleher
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40).
Journal of immunology (Baltimore, Md. : 1950) 2009;183(4):2827-36.
2009: J Judy Chang; Sunee Sirivichayakul; Anchalee Avihingsanon; Alex J V Thompson; Peter Revill; David Iser; John Slavin; Supranee Buranapraditkun; Pip Marks; Gail Matthews; David A Cooper; Stephen J Kent; paul cameron; Joe Sasadeusz; Paul Desmond; Stephen Locarnini; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.
Journal of virology 2009;83(15):7649-58.
2009: Mark Boyd; Sean Emery; David A Cooper
Antiretroviral roll-out: the problem of second-line therapy.
Lancet 2009;374(9685):185-6.
2009: Helen Byakwaga; John M Murray; Kathy Petoumenos; Anthony D Kelleher; Matthew G Law; Mark A Boyd; Sean Emery; Patrick W Mallon; David A Cooper
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
AIDS research and human retroviruses 2009;25(6):756-76.
2009: A Avihingsanon; J van der Lugt; Stephen J Kerr; M Gorowara; S Chanmano; P Ohata; Joep Lange; David A Cooper; Praphan Phanuphak; David Burger; Kiat Ruxrungtham
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.
Clinical pharmacology and therapeutics 2009;85(4):402-8.
2009: D Carey; D Baker; Kathy Petoumenos; John Chuah; G D Rogers; J Watson; David A Cooper; Sean Emery; Andrew Carr
Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
HIV medicine 2009;10(3):163-72.
2009: H Byakwaga; Jialun Zhou; Kathy Petoumenos; Matthew G Law; Mark A Boyd; Sean Emery; David A Cooper; Patrick W G Mallon
Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.
HIV medicine 2009;10(3):143-51.
2009: Kathleen Falster; Kathy Petoumenos; John Chuah; Anne Mijch; Brian Mulhall; Mark Kelly; David A Cooper
Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression.
Journal of acquired immune deficiency syndromes (1999) 2009;50(3):307-13.
2009: Nabila Seddiki; Sarah Sasson; Brigitte Santner-Nanan; Mee Ling Munier; David van Bockel; Susanna Ip; Debbie Marriott; Sarah Pett; Ralph Nanan; David A Cooper; John J Zaunders; Anthony D Kelleher
Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease.
European journal of immunology 2009;39(2):391-403.
2009: Sarah L Pett; Michael C McCarthy; David A Cooper; Karen MacRae; Amol Tendolkar; Richard Norris; Julie M Strizki; Kenneth M Williams; Sean Emery
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
Antiviral therapy 2009;14(1):111-5.
2008: Patrick W G Mallon; Rebecca Sedwell; Gary Rogers; David Nolan; Patrick Unemori; Jennifer Hoy; Katherine Samaras; Anthony D Kelleher; Sean Emery; David A Cooper; Andrew Carr
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
The Journal of infectious diseases 2008;198(12):1794-803.
2008: Christoph Boesecke; David A Cooper
Toxicity of HIV protease inhibitors: clinical considerations.
Current opinion in HIV and AIDS 2008;3(6):653-9.
2008: Gail V Matthews; Anchalee Avihingsanon; Sharon R Lewin; Janaki Amin; Rungsun Rerknimitr; Panusit Petcharapirat; Pip Marks; Joe Sasadeusz; David A Cooper; Scott Bowden; Stephen Locarnini; Kiat Ruxrungtham; Gregory J Dore
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Hepatology (Baltimore, Md.) 2008;48(4):1062-9.
2008: Kazuo Suzuki; Torsten Juelich; Heidi Lim; Takaomi Ishida; Toshiki Watanebe; David A Cooper; Sudha Rao; Anthony D Kelleher
Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region.
The Journal of biological chemistry 2008;283(34):23353-63.
2008: Jintanat Ananworanich; Thanyawee Puthanakit; Vonthanak Saphonn; David A Cooper; Kiat Ruxrungtham
Lessons from a multicentre paediatric HIV trial.
Lancet 2008;372(9636):356-7.
2008: David P Wilson; Matthew G Law; Andrew E Grulich; David A Cooper; John M Kaldor
Relation between HIV viral load and infectiousness: a model-based analysis.
Lancet 2008;372(9635):314-20.
2008: David A Cooper
Life and death in the cART era.
Lancet 2008;372(9635):266-7.
2008: David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):355-65.
2008: Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):339-54.
2008: N Voirin; J-P Routy; D Smith; Dominique Baratin; Christian Trépo; Laurent Cotte; Jean-Louis Touraine; J-M Livrozet; David A Cooper; Jacques Ritter; P André; Philippe Vanhems
Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome.
HIV medicine 2008;9(6):440-4.
2008: Jasper van der Lugt; Reshma Saskia Autar; Sasiwimol Ubolyam; Evian Fernandez Garcia; Jongkol sankote; Anchalee Avihingsanon; Anchalee Avihingson; Theshinee Chuenyam; David A Cooper; Joep Lange; Praphan Phanuphak; Ferdinand W N M Wit; Kiat Ruxrungtham; David Burger
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
The Journal of antimicrobial chemotherapy 2008;61(5):1145-53.
2008: Heidi G W Lim; Kazuo Suzuki; David A Cooper; Anthony D Kelleher
Promoter-targeted siRNAs induce gene silencing of simian immunodeficiency virus (SIV) infection in vitro.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(3):565-70.
2008: Sharon R Lewin; John M Murray; Ajantha Solomon; Fiona Wightman; paul cameron; Damian J Purcell; John J Zaunders; Pat Grey; Mark Bloch; Don Smith; David A Cooper; Anthony D Kelleher
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 2008;47(2):140-47.
2008: A Calmy; D Carey; P W G Mallon; Handan Wand; Matthew Law; David A Cooper; Andrew Carr
Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
HIV medicine 2008;9(2):101-10.
2008: Jintanat Ananworanich; Pope Kosalaraksa; Umaporn Siangphoe; Chulapan Engchanil; Chitsanu Pancharoen; Pisake Lumbiganon; Jintana Intasan; Wichitra Apateerapong; Theshinee Chuenyam; Sasiwimol Ubolyam; Torsak Bunupuradah; Joep Lange; David A Cooper; Praphan Phanuphak
A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection.
AIDS research and therapy 2008;5():24.
2007: Dianne L Carey; David Baker; Gary D Rogers; Kathy Petoumenos; John Chuah; Nicole Easey; Kirsty Machon; David A Cooper; Sean Emery; Andrew Carr
A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.
Journal of acquired immune deficiency syndromes (1999) 2007;46(5):581-9.
2007: Handan Wand; Alexandra Calmy; Dianne L Carey; Katherine Samaras; Andrew Carr; Matthew G Law; David A Cooper; Sean Emery
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
AIDS (London, England) 2007;21(18):2445-53.
2007: John M Murray; Sean Emery; Anthony D Kelleher; Matthew Law; Joshua Chen; Daria J Hazuda; Bach-Yen T Nguyen; Hedy Teppler; David A Cooper
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
AIDS (London, England) 2007;21(17):2315-21.
2007: Sean Emery; Anthony D Kelleher; Cassy Workman; Rebekah L Puls; M Bloch; D Baker; J Anderson; Jennifer Hoy; S Ip; K Nalliah; L D Ward; Matthew G Law; David A Cooper
Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy.
Human vaccines 2007;3(6):260-7.
2007: David van Bockel; David A Price; Tedi E Asher; Vanessa Venturi; Kazuo Suzuki; Kristina Warton; Miles P Davenport; David A Cooper; Daniel C Douek; Anthony D Kelleher
Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood.
Journal of immunological methods 2007;326(1-2):127-38.
2007: I M Poynten; D E Smith; David A Cooper; John M Kaldor; Andrew E Grulich
The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV.
HIV medicine 2007;8(6):374-81.
2007: Jacques Reynes; Keikawus Arastéh; Bonaventura Clotet; Calvin Cohen; David A Cooper; Jean-François Delfraissy; Joseph J Eron; Keith Henry; Christine Katlama; Daniel R Kuritzkes; Jacob P Lalezari; Joep Lange; Adriano Lazzarin; Julio S G Montaner; Mark Nelson; Mary O' Hearn; Hans-Jürgen Stellbrink; Benoit Trottier; Sharon L Walmsley; Neil E Buss; Ralph DeMasi; Jain Chung; Lucille Donatacci; Denise Guimaraes; Lucy Rowell; Adeline Valentine; Martin Wilkinson; Miklos Salgo
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
2007: Gregory J Dore; Francesca J Torriani; Maribel Rodriguez-Torres; Norbert Bräu; Mark S Sulkowski; Ricard Sola Lamoglia; Cristina Tural; Nathan Clumeck; Mark R Nelson; Maria C Mendes-Correa; Eliot W Godofsky; Douglas T Dieterich; Ellen Yetzer; Eduardo Lissen; David A Cooper
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
AIDS (London, England) 2007;21(12):1555-9.
2007: Reshma Saskia Autar; Ferdinand W N M Wit; Jongkol sankote; Duanghathai Sutthichom; Elly Kimenai; Elly A M Hassink; Andrew Hill; David A Cooper; Praphan Phanuphak; Joep M A Lange; David Burger; Kiat Ruxrungtham
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.
AIDS (London, England) 2007;21(12):1535-9.
2007: Alexandra Calmy; Bernard Hirschel; David A Cooper; Andrew Carr
Clinical update: adverse effects of antiretroviral therapy.
Lancet 2007;370(9581):12-4.
2007: Mark A Boyd; David A Cooper
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research.
AIDS (London, England) 2007;21 Suppl 4():S55-63.
2007: Mark R Nelson; Christine Katlama; Julio S G Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS (London, England) 2007;21(10):1273-81.
2007: Alan Winston; Patrick W G Mallon; Claudette Satchell; Karen MacRae; Kenneth M Williams; Malte Schutz; Matthew Law; David A Cooper; Sean Emery
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(11):1475-83.
2007: Stephen J Kerr; Chris Duncombe; Anchalee Avihingsanon; Jintanat Ananworanich; Mark Boyd; Bunruan Sopa; B Medtech; Theshinee Chuenyam; David A Cooper; Joep M A Lange; Praphan Phanuphak; Kiat Ruxrungtham
Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2007;6(1):36-46.
2007: Reshma Saskia Autar; Mark A Boyd; Ferdinand W N M Wit; Kiat Ruxrungthams; Jongkol sankote; Joep Lange; David A Cooper; Praphan Phanuphak; David Burger; Peter Reiss
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
Antiviral therapy 2007;12(8):1265-71.
2007: Gail V Matthews; David A Cooper; Gregory J Dore
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Antiviral therapy 2007;12(1):119-22.
2007: Preeyaporn Srasuebkul; Chaiwat Ungsedhapand; Kiat Ruxrungtham; Mark A Boyd; Praphan Phanuphak; David A Cooper; Matthew G Law
Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
HIV medicine 2007;8(1):46-54.
2007: Jialun Zhou; Nicholas Paton; Rossana Ditangco; Y-M A Chen; Adeeba Kamarulzaman; N Kumarasamy; C K C Lee; P C K Li; T P Merati; Praphan Phanuphak; S Pujari; Asda Vibhagool; Fujie Zhang; John Chuah; K R Frost; David A Cooper; Matthew G Law
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
HIV medicine 2007;8(1):8-16.
2007: Wayne B Dyer; Sarah L Pett; John Sullivan; Sean Emery; David A Cooper; Anthony D Kelleher; Andrew Lloyd; Sharon R Lewin
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples.
Clinical and vaccine immunology : CVI 2007;14(1):52-9.
2006: Joseph C Gathe; David A Cooper; Charles Farthing; Dushyantha Jayaweera; Dorece Norris; Gerald Pierone; Corklin R Steinhart; Benoit Trottier; Sharon L Walmsley; Cassy Workman; Geoffrey Mukwaya; Veronika Kohlbrenner; Catherine Dohnanyi; Scott McCallister; Douglas Mayers
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(10):1337-46.
2006: Mark A Boyd; Narendra M Dixit; Umaporn Siangphoe; Neil E Buss; Miklos Salgo; Joep M A Lange; Praphan Phanuphak; David A Cooper; Alan S Perelson; Kiat Ruxrungtham
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
The Journal of infectious diseases 2006;194(9):1319-22.
2006: John J Zaunders; Susanna Ip; Mee Ling Munier; Daniel E Kaufmann; Kazuo Suzuki; Choechoe Brereton; Sarah Sasson; Nabila Seddiki; Kersten Koelsch; Alan Landay; Pat Grey; Robert Finlayson; John Kaldor; Eric S Rosenberg; Bruce D Walker; Barbara Fazekas De St Groth; David A Cooper; Anthony D Kelleher
Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection.
Journal of virology 2006;80(20):10162-72.
2006: John J Zaunders; Wayne B Dyer; Mee Ling Munier; Susanna Ip; Jie Liu; Elisabeth Amyes; William D Rawlinson; Robert De Rose; Stephen J Kent; John Sullivan; David A Cooper; Anthony D Kelleher
CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells.
Journal of virology 2006;80(20):10151-61.
2006: Mark A Boyd; Andrew Carr; Kiat Ruxrungtham; Preeyaporn Srasuebkul; Darl Bien; Matthew Law; Somjai Wangsuphachart; Anchali Krisanachinda; Sakalaya Lerdlum; Joep M A Lange; Praphan Phanuphak; David A Cooper; Peter Reiss
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
The Journal of infectious diseases 2006;194(5):642-50.
2006: Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Lancet 2006;368(9534):466-75.
2006: Gregory J Dore; David A Cooper
HAART's first decade: success brings further challenges.
Lancet 2006;368(9534):427-8.
2006: Patrick Yeni; David A Cooper; Jean-Pierre Aboulker; A G Babiker; D Carey; Janet Darbyshire; Marco Floridia; P M Girard; Ruth L Goodall; Malcolm H Hooker; A Mijch; Vincent Meiffredy; B Salzberger
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
Lancet 2006;368(9532):287-98.
2006: Mark T Bloch; Don E Smith; Dick Quan; John M Kaldor; John J Zaunders; Kathy Petoumenos; Kathy Irvine; Matthew Law; Pat Grey; Robert Finlayson; Robert McFarlane; Anthony D Kelleher; Andrew Carr; David A Cooper
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
Journal of acquired immune deficiency syndromes (1999) 2006;42(2):192-202.
2006: Mark A Boyd; Umaporn Siangphoe; Kiat Ruxrungtham; Peter Reiss; Apicha Mahanontharit; Joep M A Lange; Praphan Phanuphak; David A Cooper; David Burger
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
The Journal of antimicrobial chemotherapy 2006;57(6):1161-7.
2006: Robert De Rose; Mark T Sullivan; C Jane Dale; Anthony D Kelleher; Sean Emery; David A Cooper; Ian A Ramshaw; David B Boyle; Stephen J Kent
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials.
Human vaccines 2006;2(3):134-6.
2006: Mark A Boyd; Preeyaporn Srasuebkul; Kiat Ruxrungtham; Peter I Mackenzie; Verawan Uchaipichat; Michael Stek; Joep M A Lange; Praphan Phanuphak; David A Cooper; Wandee Udomuksorn; John O Miners
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.
Pharmacogenetics and genomics 2006;16(5):321-9.
2006: Patrick W G Mallon; John Miller; Jason C Kovacic; Julia Kent-Hughes; Richard Norris; Katherine Samaras; Michael P Feneley; David A Cooper; Andrew Carr
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
AIDS (London, England) 2006;20(7):1003-10.
2006: Gail V Matthews; Angeline Bartholomeusz; Stephen Locarnini; Anna Ayres; Joe Sasaduesz; Eric C Seaberg; David A Cooper; Sharon Lewin; Gregory J Dore; Chloe L Thio
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
AIDS (London, England) 2006;20(6):863-70.
2006: Alan Winston; Janaki Amin; Gillian Hales; David A Cooper; Sean Emery
Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals.
AIDS research and human retroviruses 2006;22(4):338-41.
2006: Alan Winston; Janaki Amin; Patrick W G Mallon; Debbie Marriott; Andrew Carr; David A Cooper; Sean Emery
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
HIV medicine 2006;7(2):105-11.
2006: Sarah Sasson; John J Zaunders; giulia zanetti; Eleanor M King; Kate M Merlin; Don E Smith; Keith K Stanley; David A Cooper; Anthony D Kelleher
Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection.
The Journal of infectious diseases 2006;193(4):505-14.
2006: Elizabeth Hamlyn; J McAllister; A Winston; B Sinclair; Janaki Amin; Andrew Carr; David A Cooper
Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?
Sexually transmitted infections 2006;82(1):21-3.
2006: Anthony D Kelleher; Rebekah L Puls; Mark Bebbington; David Boyle; Rosemary Ffrench; Stephen J Kent; Susan Kippax; Damian F J Purcell; Scott Thomson; Handan Wand; David A Cooper; Sean Emery
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
AIDS (London, England) 2006;20(2):294-7.
2006: Mark A Boyd; Preeyaporn Srasuebkul; Mana Khongphattanayothin; Kiat Ruxrungtham; Elly A M Hassink; Chris Duncombe; Sasiwimol Ubolyam; David Burger; Peter Reiss; Michael Stek; Joep Lange; David A Cooper; Praphan Phanuphak
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Antiviral therapy 2006;11(2):223-32.
2006: Matthew Law; Rebekah L Puls; Andrew K Cheng; David A Cooper; Andrew Carr
Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults.
Antiviral therapy 2006;11(2):179-86.
2005: Mark Nelson; Keikawus Arastéh; Bonaventura Clotet; David A Cooper; Keith Henry; Christine Katlama; Jacob P Lalezari; Adriano Lazzarin; Julio S G Montaner; Mary E O'Hearn; Peter J Piliero; Jacques Reynes; Benoit Trottier; Sharon L Walmsley; Calvin Cohen; Joseph J Eron; Daniel R Kuritzkes; Joep Lange; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Neil E Buss; Lucille Donatacci; Cynthia Wat; Lynn Smiley; Martin Wilkinson; Adeline Valentine; Denise Guimaraes; Ralph DeMasi; Jain Chung; Miklos Salgo
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Sean Emery; Cassy Workman; Rebekah L Puls; M Bloch; D Baker; NJ Bodsworth; J Anderson; Suzanne M Crowe; Martyn A French; Jennifer Hoy; A Aichelburg; L D Ward; David B Boyle; Matthew G Law; Anthony D Kelleher; David A Cooper
Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.
Human vaccines 2005;1(6):232-8.
2005: Mark A Boyd; Umaporn Siangphoe; Kiat Ruxrungtham; Chris Duncombe; Michael Stek; Joep M A Lange; David A Cooper; Praphan Phanuphak
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
HIV medicine 2005;6(6):410-20.
2005: Reshma Saskia Autar; Marta Boffito; Elly A M Hassink; Ferdinand W N M Wit; Jintanat Ananworanich; Umaporn Siangphoe; Anton Pozniak; David A Cooper; Praphan Phanuphak; Joep M A Lange; Kiat Ruxrungtham; David Burger
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.
The Journal of antimicrobial chemotherapy 2005;56(5):908-13.
2005: Alan Winston; Gillian Hales; Janaki Amin; Erno van Schaick; David A Cooper; Sean Emery
The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals.
AIDS (London, England) 2005;19(13):1393-9.
2005: John J Zaunders; Mee Ling Munier; Daniel E Kaufmann; Susanna Ip; Pat Grey; Don Smith; Tim Ramacciotti; Dick Quan; Robert Finlayson; John Kaldor; Eric S Rosenberg; Bruce D Walker; David A Cooper; Anthony D Kelleher
Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection.
Blood 2005;106(5):1660-7.
2005: Dianne Carey; Handan Wand; Allison Martin; Sharyn Rothwell; Sean Emery; David A Cooper; Andrew Carr
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial.
AIDS (London, England) 2005;19(12):1325-7.
2005: Sarah Sasson; Anthony D Kelleher; David A Cooper
The modern ART of HIV infection management: towards a tailored approach to maximize CD4 T cell reconstitution.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(3):373-5.
2005: Alan Winston; Mark Bloch; Andrew Carr; Janaki Amin; Patrick W G Mallon; John Ray; Debbie Marriott; David A Cooper; Sean Emery
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
The Journal of antimicrobial chemotherapy 2005;56(2):380-7.
2005: Patrick W G Mallon; Patrick Unemori; Rebecca Sedwell; Adrienne Morey; Martina Rafferty; Kenneth Williams; Donald Chisholm; Katherine Samaras; Sean Emery; Anthony D Kelleher; David A Cooper; Andrew Carr
In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.
The Journal of infectious diseases 2005;191(10):1686-96.
2005: Palanee Ammaranond; John J Zaunders; Claudette Satchell; David van Bockel; David A Cooper; Anthony D Kelleher
A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1.
AIDS research and human retroviruses 2005;21(5):395-7.
2005: Peter Cardiello; Elly A M Hassink; Jintanat Ananworanich; Preeyaporn Srasuebkul; Tarika Samor; Apicha Mahanontharit; Kiat Ruxrungtham; Bernard Hirschel; Joep Lange; Praphan Phanuphak; David A Cooper
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(4):594-600.
2005: Jialun Zhou; N Kumarasamy; Rossana Ditangco; Adeeba Kamarulzaman; Christopher K C Lee; Patrick C K Li; Nicholas Paton; Praphan Phanuphak; Sanjay Pujari; Asda Vibhagool; Wing-Wai Wong; Fujie Zhang; John Chuah; Kevin R Frost; David A Cooper; Matthew G Law
The TREAT Asia HIV Observational Database: baseline and retrospective data.
Journal of acquired immune deficiency syndromes (1999) 2005;38(2):174-9.
2005: Patrick W G Mallon; Handan Wand; Matthew Law; John Miller; David A Cooper; Andrew Carr
Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia.
Journal of acquired immune deficiency syndromes (1999) 2005;38(2):156-62.
2005: Jintanat Ananworanich; Zewlan Moor; Umaporn Siangphoe; Jason Chan; Peter Cardiello; Chris Duncombe; Praphan Phanuphak; Kiat Ruxrungtham; Joep Lange; David A Cooper
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
AIDS (London, England) 2005;19(2):185-92.
2005: Chris Duncombe; Stephen J Kerr; Kiat Ruxrungtham; Gregory J Dore; Matthew G Law; Sean Emery; Joep M A Lange; Praphan Phanuphak; David A Cooper
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting.
AIDS (London, England) 2005;19(2):169-78.
2005: Reshma Saskia Autar; Ferdinand W N M Wit; Jongkol sankote; Apicha Mahanontharit; Thanomsak Anekthananon; Piroon Mootsikapun; Khanjtta Sujaikaew; David A Cooper; Joep M A Lange; Praphan Phanuphak; Kiat Ruxrungtham; David Burger
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Antiviral therapy 2005;10(8):937-43.
2005: Jintanat Ananworanich; Andrew Hill; Umaporn Siangphoe; Kiat Ruxrungtham; Wisit Prasithsirikul; Ploenchan Chetchotisakd; Sasisopin Kiertiburanakul; Warangkana Munsakul; Phitsanu Raksakulkarn; Somboon Tansuphasawadikul; Reto Nüesch; David A Cooper; Bernard Hirschel
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Antiviral therapy 2005;10(6):761-7.
2005: Patrick W G Mallon; Rebecca Sedwell; Patrick Unemori; Anthony D Kelleher; David A Cooper; Andrew Carr
Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy.
Antiviral therapy 2005;10 Suppl 2():M101-8.
2005: Jason C Kovacic; Allison Martin; Dianne Carey; Handan Wand; Patrick W G Mallon; Michael P Feneley; Sean Emery; David A Cooper; Andrew Carr
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Antiviral therapy 2005;10(1):135-43.
2004: Philippe Vanhems; Nicolas Voirin; Pierre Philippe; Bernard Hirschel; Joelle Brassard; Andrew Carr; David A Cooper; Luc Perrin; Robert Allard
The incubation period of acute retroviral syndrome as a multistep process: a parametric survival analysis.
Journal of acquired immune deficiency syndromes (1999) 2004;37(4):1529-33.
2004: C Jane Dale; Robert De Rose; Kim M Wilson; Hayley A Croom; Scott Thomson; Barbara E H Coupar; Alistair Ramsay; Damian F J Purcell; Rosemary Ffrench; Matthew Law; Sean Emery; David A Cooper; Ian A Ramshaw; David B Boyle; Stephen J Kent
Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12.
Vaccine 2004;23(2):188-97.
2004: Kelly Safreed-Harmon; David A Cooper; Joep M A Lange; Chris Duncombe; Praphan Phanuphak
The HIV Netherlands Australia Thailand research collaboration: lessons from 7 years of clinical research.
AIDS (London, England) 2004;18(15):1971-8.
2004: Allison Martin; Don Smith; Andrew Carr; Jennifer Hoy; John Chuah; Simon Mallal; Matthew Law; Mark Clements; David A Cooper
Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study).
HIV clinical trials 2004;5(4):192-200.
2004: David A Cooper; Joep M A Lange
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
The Lancet infectious diseases 2004;4(7):426-36.
2004: Chaiwat Ungsedhapand; Preeyaporn Srasuebkul; Peter Cardiello; Kiat Ruxrungtham; Winai Ratanasuwan; Eugene D M B Kroon; Metta Tongtalung; Nittaya Juengprasert; Sasiwimol Ubolyam; Umaporn Siangphoe; Sean Emery; Joep M A Lange; David A Cooper; Praphan Phanuphak
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):693-701.
2004: W. Phillip Law; Chris Duncombe; Apicha Mahanontharit; Mark A Boyd; Kiat Ruxrungtham; Joep M A Lange; Praphan Phanuphak; David A Cooper; Gregory J Dore
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.
AIDS (London, England) 2004;18(8):1169-77.
2004: Janaki Amin; M Kaye; S Skidmore; D Pillay; David A Cooper; Gregory J Dore
HIV and hepatitis C coinfection within the CAESAR study.
HIV medicine 2004;5(3):174-9.
2004: Allison Martin; Don E Smith; Andrew Carr; Clare Ringland; Janaki Amin; Sean Emery; Jennifer Hoy; Cassy Workman; Nicholas Doong; Judith Freund; David A Cooper
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
AIDS (London, England) 2004;18(7):1029-36.
2004: Gregory J Dore; David A Cooper; Anton L Pozniak; Edwin DeJesus; Lijie Zhong; Michael D Miller; Biao Lu; Andrew K Cheng
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
The Journal of infectious diseases 2004;189(7):1185-92.
2004: John J Zaunders; Wayne B Dyer; Bin Wang; Mee Ling Munier; Monica Miranda-Saksena; Rebecca Newton; John Moore; Charles R Mackay; David A Cooper; Nitin K Saksena; Anthony D Kelleher
Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection.
Blood 2004;103(6):2238-47.
2004: Andrew Carr; Cassy Workman; Dianne Carey; Gary Rogers; Allison Martin; David Baker; Handan Wand; Matthew Law; Katherine Samaras; Sean Emery; David A Cooper
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
Lancet 2004;363(9407):429-38.
2003: Elizabeth Keoshkerian; Lesley J Ashton; Danielle G Smith; John B Ziegler; John M Kaldor; David A Cooper; Graeme J Stewart; Rosemary A Ffrench
Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.
Journal of medical virology 2003;71(4):483-91.
2003: W. Phillip Law; Gregory J Dore; Chris Duncombe; Apicha Mahanontharit; Mark A Boyd; Kiat Ruxrungtham; Joep M A Lange; Praphan Phanuphak; David A Cooper
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
AIDS (London, England) 2003;17(15):2191-9.
2003: Mark A Boyd; Rob E Aarnoutse; Kiat Ruxrungtham; Michael Stek; Rolf P G van Heeswijk; Joep M A Lange; David A Cooper; Praphan Phanuphak; David Burger
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;34(2):134-9.
2003: J Amin; A Moore; Andrew Carr; M A French; Matthew Law; Sean Emery; David A Cooper
Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
HIV clinical trials 2003;4(4):252-61.
2003: John Miller; Andrew Carr; Sean Emery; Matthew Law; Simon Mallal; D Baker; Don Smith; John Kaldor; David A Cooper
HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.
HIV medicine 2003;4(3):293-301.
2003: Peter Cardiello; Tarika Samor; David Burger; Richard Hoetelmans; Apicha Mahanontharit; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients.
Antiviral therapy 2003;8(3):245-9.
2003: John J Zaunders; Laure Moutouh-de Parseval; Shinichi Kitada; John C Reed; Steffney Rought; Davide Genini; Lorenzo Leoni; Anthony D Kelleher; David A Cooper; Don E Smith; Pat Grey; Jérôme Estaquier; Susan Little; Douglas D Richman; Jacques Corbeil
Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2.
The Journal of infectious diseases 2003;187(11):1735-47.
2003: Patrick W G Mallon; John Miller; David A Cooper; Andrew Carr
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
AIDS (London, England) 2003;17(7):971-9.
2003: Philippe Vanhems; Nicolas Voirin; Bernard Hirschel; David A Cooper; Jeanette Vizzard; Andrew Carr; Luc Perrin
Brief report: incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS.
Journal of acquired immune deficiency syndromes (1999) 2003;32(5):542-4.
2003: Peter Cardiello; Tarkika Monhaphol; Apicha Mahanontharit; Rolf P G van Heeswijk; David Burger; Andrew Hill; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;32(4):375-9.
2003: Don E Smith; Gilbert R Kaufmann; James O Kahn; Frederick Hecht; Pat Grey; John J Zaunders; Philip H Cunningham; Andrew Carr; Chris Duncombe; Dick Quan; Annkatrin Petersen; David A Cooper
Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.
AIDS research and human retroviruses 2003;19(3):189-99.
2003: Patrick W G Mallon; John Ray; David A Cooper
Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003;26(2):223-7.
2003: Palanee Ammaranond; Philip Cunningham; Robert Oelrichs; Kazuo Suzuki; Claire Harris; Leakhena Leas; Andrew Grulich; David A Cooper; Anthony D Kelleher
Rates of transmission of antiretroviral drug resistant strains of HIV-1.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003;26(2):153-61.
2003: Palanee Ammaranond; Philip Cunningham; Robert Oelrichs; Kazuo Suzuki; Claire Harris; Leakhena Leas; Andrew Grulich; David A Cooper; Anthony D Kelleher
No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001.
AIDS (London, England) 2003;17(2):264-7.
2003: Don E Smith; Jeff Hudson; Allison Martin; Judith Freund; Matthew R Griffiths; Sue Kalnins; Matthew Law; Andrew Carr; David A Cooper
Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy.
HIV clinical trials 2003;4(1):45-9.
2002: Bin Wang; Wayne B Dyer; John J Zaunders; Meriet Mikhail; John Sullivan; Lisa Williams; Da'ed N Haddad; Graeme Harris; John A G Holt; David A Cooper; Monica Miranda-Saksena; Ross A Boadle; Anthony D Kelleher; Nitin K Saksena
Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection.
Virology 2002;304(2):246-64.
2002: Don E Smith; Andrew Carr; Matthew Law; Allison Martin; Jeff Hudson; Jennifer Hoy; David A Cooper
Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study.
AIDS (London, England) 2002;16(18):2489-91.
2002: Sarah L Pett; Greg J Dore; Robert J Fielden; David A Cooper
Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1.
AIDS (London, England) 2002;16(17):2364-5.
2002: Philippe Vanhems; Emmanuelle Caillat-Vallet; Bernard Hirschel; Jean-Pierre Routy; Andrew Carr; Jeanette Vizzard; David A Cooper; Luc Perrin
The CD4 cell count 3 months after acute retroviral syndrome is associated with the presence of AIDS in the source individual.
AIDS (London, England) 2002;16(16):2234-6.
2002: Philippe Vanhems; Jean-Pierre Routy; Bernard Hirschel; Dominique Baratin; Samir Vora; Janine Maenza; Andrew Carr; Christian Trépo; Jean-Louis Touraine; René-Pierre Gillibert; Ann C Collier; David A Cooper; Jeanette Vizzard; Rafick-Pierre Sékaly; Jacques Fabry; Luc Perrin
Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age.
Journal of acquired immune deficiency syndromes (1999) 2002;31(3):318-21.
2002: Andrew Carr; Cassy Workman; Don E Smith; Jennifer Hoy; Jeff Hudson; Nicholas Doong; Allison Martin; Janaki Amin; Judith Freund; Matthew Law; David A Cooper
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
JAMA : the journal of the American Medical Association 2002;288(2):207-15.
2002: Victor Appay; John J Zaunders; Laura Papagno; Julian Sutton; Angel Jaramillo; Anele Waters; Philippa Easterbrook; Pat Grey; Don Smith; Andrew J McMichael; David A Cooper; Sarah L Rowland-Jones; Anthony D Kelleher
Characterization of CD4(+) CTLs ex vivo.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(11):5954-8.
2002: Peter Cardiello; Rolf P G van Heeswijk; Elly A M Hassink; Preeyaporn Srasuebkul; Apicha Mahanontharit; Tarika Samor; Wassana Worarien; Jos H Beijnen; Richard Hoetelmans; Kiat Ruxrungtham; David A Cooper; Joep M A Lange; Praphan Phanuphak
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):464-70.
2002: Chokechai Rongkavilit; Rolf P G van Heeswijk; Sompop Limpongsanurak; Pimolrat Thaithumyanon; Chantana Boonrod; Elly A M Hassink; Aeumporn Srigritsanapol; Theshinee Chuenyam; Sasiwimol Ubolyam; Richard Hoetelmans; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):455-63.
2002: Patrick W G Mallon; Andrew Carr; David A Cooper
HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways.
Current diabetes reports 2002;2(2):116-24.
2002: Lesley J Ashton; Graeme J Stewart; Robyn Biti; Matthew Law; David A Cooper; John M Kaldor
Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens.
HIV medicine 2002;3(2):91-6.
2002: Sean Emery; Donald I Abrams; David A Cooper; Janet H Darbyshire; H Clifford Lane; Jens D Lundgren; James D Neaton
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.
Controlled clinical trials 2002;23(2):198-220.
2002: Gilbert R Kaufmann; Mark Bloch; Robert Finlayson; John J Zaunders; Don Smith; David A Cooper
The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.
AIDS (London, England) 2002;16(3):359-67.
2002: Sean Emery; David A Cooper
HIV medicine.
The Medical journal of Australia 2002;176(1):21.
2002: David A Cooper
Update on didanosine.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2002;1(1):15-25.
2002: J Wilkinson; John J Zaunders; Andrew Carr; Gilles GUILLEMIN; David A Cooper
Characterization of the phenotypic and lymphokine profile associated with strong CD8+ anti-HIV-1 suppressor activity (CASA).
Clinical and experimental immunology 2002;127(1):145-50.
2001: Gregory J Dore; David A Cooper
The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.
Current opinion in infectious diseases 2001;14(6):749-55.
2001: Chokechai Rongkavilit; Pimolrat Thaithumyanon; Theshinee Chuenyam; B D Damle; Sompop Limpongsanurak; C Boonrod; A Srigritsanapol; Elly A M Hassink; Richard Hoetelmans; David A Cooper; Joep M A Lange; Kiat Ruxrungtham; Praphan Phanuphak
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
Antimicrobial agents and chemotherapy 2001;45(12):3585-90.
2001: Don Smith; I Gow; Robert Colebunders; I Weller; S Tchamouroff; J Weber; F Boag; Gillian Hales; S Adams; G Patou; David A Cooper
Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline.
HIV medicine 2001;2(4):272-5.
2001: Andrew Carr; Jeff Hudson; John Chuah; Simon Mallal; Matthew Law; Jennifer Hoy; Nicholas Doong; Martyn French; Don Smith; David A Cooper
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
AIDS (London, England) 2001;15(14):1811-22.
2001: Kazuo Suzuki; Gilbert R Kaufmann; Motokazu Mukaide; Philip Cunningham; Claire Harris; Leakhena Leas; M Kondo; M Imai; Sarah L Pett; Robert Finlayson; John J Zaunders; Anthony D Kelleher; David A Cooper
Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.
AIDS research and human retroviruses 2001;17(13):1293-6.
2001: Patrick W G Mallon; David A Cooper; Andrew Carr
HIV-associated lipodystrophy.
HIV medicine 2001;2(3):166-73.
2001: Chaiwat Ungsedhapand; Eugene D M B Kroon; Surapol Suwanagool; Kiat Ruxrungtham; N Yimsuan; Areeaue Sonjai; Sasiwimol Ubolyam; Supranee Buranapraditkun; Surapee Tiengrim; Nadine Pakker; Chaiyos Kunanusont; Joep M A Lange; David A Cooper; Praphan Phanuphak
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Journal of acquired immune deficiency syndromes (1999) 2001;27(2):116-23.
2001: Andrew Carr; John Miller; J A Eisman; David A Cooper
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
AIDS (London, England) 2001;15(6):703-9.
2001: Gilbert R Kaufmann; Kazuo Suzuki; Philip Cunningham; Motokazu Mukaide; M Kondo; M Imai; John J Zaunders; David A Cooper
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
AIDS research and human retroviruses 2001;17(6):487-97.
2001: John J Zaunders; Gilbert R Kaufmann; Philip H Cunningham; Don Smith; Pat Grey; Kazuo Suzuki; Andrew Carr; L E Goh; David A Cooper
Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 2001;183(5):736-43.
2001: Gilbert R Kaufmann; John J Zaunders; J Murray; Anthony D Kelleher; Sharon R Lewin; A Solomon; D Smith; David A Cooper
Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling.
AIDS research and human retroviruses 2001;17(2):147-59.
2000: Gilbert R Kaufmann; John J Zaunders; Philip Cunningham; Anthony D Kelleher; Pat Grey; Don Smith; Andrew Carr; David A Cooper
Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.
AIDS (London, England) 2000;14(17):2643-51.
2000: Andrew Carr; David A Cooper
Adverse effects of antiretroviral therapy.
Lancet 2000;356(9239):1423-30.
2000: John Miller; Andrew Carr; Don Smith; Sean Emery; Matthew G Law; Pat Grey; David A Cooper
Lipodystrophy following antiretroviral therapy of primary HIV infection.
AIDS (London, England) 2000;14(15):2406-7.
2000: Philip H Cunningham; Danielle G Smith; C Satchell; David A Cooper; Bruce J Brew
Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.
AIDS (London, England) 2000;14(13):1949-54.
2000: Don Smith; M M Berrey; M Robertson; D Mehrotra; M Markowitz; L Perrin; Nathan Clumeck; A Lazzarin; B Burckhardt; R Weber; L Corey; David A Cooper
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 2000;182(3):950-4.
2000: Sean Emery; W B Capra; David A Cooper; Ronald T Mitsuyasu; Joseph A Kovacs; P Vig; M Smolskis; Louis D Saravolatz; H Clifford Lane; Gwendolyn Fyfe; P T Curtin
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease.
The Journal of infectious diseases 2000;182(2):428-34.
2000: Kiat Ruxrungtham; Eugene D M B Kroon; Chaiwat Ungsedhapand; Somsong Teeratakulpisarn; Sasiwimol Ubolyam; Supranee Buranapraditkun; R van Leeuwen; Gerrit Jan Weverling; Chaiyos Kunanusont; Joep M A Lange; David A Cooper; Praphan Phanuphak
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
AIDS (London, England) 2000;14(10):1375-82.
2000: Eugene D M B Kroon; Chaiwat Ungsedhapand; Kiat Ruxrungtham; M Chuenyam; Sasiwimol Ubolyam; M E Newell; R van Leeuwen; Chaiyos Kunanusont; S Buranapraditkul; Sunee Sirivichayakul; Joep M A Lange; David A Cooper; Praphan Phanuphak
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
AIDS (London, England) 2000;14(10):1349-56.
2000: Philippe Vanhems; Bernard Hirschel; A N Phillips; David A Cooper; Jeanette Vizzard; J Brassard; Luc Perrin
Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS.
The Journal of infectious diseases 2000;182(1):334-7.
2000: Andrew Carr; John Chuah; Jeff Hudson; Martyn French; Jennifer Hoy; Matthew Law; David C Sayer; Sean Emery; David A Cooper
A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
AIDS (London, England) 2000;14(9):1171-80.
2000: Philippe Vanhems; R Gaudet; Bernard Hirschel; A Imrie; Brian Conway; Danielle Rouleau; Jeanette Vizzard; Luc Perrin; David A Cooper; S Yerly
Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
AIDS (London, England) 2000;14(8):1065-7.
2000: Gilbert R Kaufmann; Mark Bloch; John J Zaunders; Don Smith; David A Cooper
Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
AIDS (London, England) 2000;14(8):959-69.
2000: Philippe Vanhems; J Hughes; Ann C Collier; Jeanette Vizzard; Luc Perrin; David A Cooper; Bernard Hirschel; L Corey
Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney.
AIDS (London, England) 2000;14(4):375-81.
2000: Andrew Carr; John Miller; Matthew Law; David A Cooper
A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
AIDS (London, England) 2000;14(3):F25-32.
2000: Matthew G Law; Yueming Li; Ann M McDonald; David A Cooper; John M Kaldor
Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection.
AIDS (London, England) 2000;14(2):197-201.
2000: Andrew E Grulich; X Wan; Matthew G Law; Sam Milliken; C R Lewis; R J Garsia; J Gold; Robert Finlayson; David A Cooper; John M Kaldor
B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS.
AIDS (London, England) 2000;14(2):133-40.
1999: Gilbert R Kaufmann; P Cunningham; John J Zaunders; M Law; J Vizzard; Andrew Carr; David A Cooper
Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group.
Journal of acquired immune deficiency syndromes (1999) 1999;22(5):437-44.
1999: John J Zaunders; Andrew F Geczy; Wayne B Dyer; LB McIntyre; Margaret Cooley; LJ Ashton; CH Raynes-Greenow; Jennifer C Learmont; David A Cooper; John Sullivan
Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes.
AIDS research and human retroviruses 1999;15(17):1519-27.
1999: Gregory J Dore; David A Cooper; C Barrett; L E Goh; B Thakrar; M Atkins
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
The Journal of infectious diseases 1999;180(3):607-13.
1999: G R Kaufmann; John J Zaunders; David A Cooper
Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.
Sexually transmitted infections 1999;75(4):218-24.
1999: John J Zaunders; Philip H Cunningham; Anthony D Kelleher; Gilbert R Kaufmann; Angel Jaramillo; R Wright; Don Smith; Pat Grey; J Vizzard; Andrew Carr; David A Cooper
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
The Journal of infectious diseases 1999;180(2):320-9.
1999: Gilbert R Kaufmann; John J Zaunders; Philip Cunningham; David A Cooper
Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.
AIDS research and human retroviruses 1999;15(11):963-72.
1999: Gregory J Dore; Patty Correll; Yueming Li; John M Kaldor; David A Cooper; Bruce J Brew
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.
AIDS (London, England) 1999;13(10):1249-53.
1999: J Wilkinson; John J Zaunders; Andrew Carr; David A Cooper
CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia.
The Journal of infectious diseases 1999;180(1):68-75.
1999: Philippe Vanhems; C Dassa; J Lambert; David A Cooper; Luc Perrin; Jeanette Vizzard; Bernard Hirschel; S Kinloch-de Loës; Andrew Carr; Robert Allard
Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 1999;21(2):99-106.
1999: Andrew E Grulich; S J Olsen; K Luo; Olympia Hendry; Philip Cunningham; David A Cooper; Shou-Jiang Gao; Yuan Chang; Patrick S Moore; John M Kaldor
Kaposi's sarcoma-associated herpesvirus: a sexually transmissible infection?
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999;20(4):387-93.
1999: Philippa J Easterbrook; Ruth L Goodall; Abdel G Babiker; L M Yu; D Smith; David A Cooper; Brian G Gazzard
Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?
The Journal of antimicrobial chemotherapy 1999;43(3):379-88.
1999: Matthew G Law; L de Winter; Ann McDonald; David A Cooper; John M Kaldor
AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment.
AIDS (London, England) 1999;13(2):263-9.
1999: E M Benson; J Clarkson; M Law; P Marshall; Anthony D Kelleher; Don E Smith; G Patou; Graeme J Stewart; David A Cooper; R A French
Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals.
AIDS research and human retroviruses 1999;15(2):105-13.
1998: Andrew Carr; David A Cooper
HIV and AIDS. Gap between biology and reality in AIDS.
Lancet 1998;352 Suppl 4():SIV16.
1998: JM Murray; Gilbert R Kaufmann; Anthony D Kelleher; David A Cooper
A model of primary HIV-1 infection.
Mathematical biosciences 1998;154(2):57-85.
1998: M Newell; Sam Milliken; D Goldstein; C Lewis; M Boyle; G Dolan; S Ryan; David A Cooper
A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma.
Australian and New Zealand journal of medicine 1998;28(6):777-83.
1998: Gilbert R Kaufmann; P Cunningham; Anthony D Kelleher; John J Zaunders; Andrew Carr; J Vizzard; M Law; David A Cooper
Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.
The Journal of infectious diseases 1998;178(6):1812-5.
1998: Patty Correll; Matthew G Law; Ann M McDonald; David A Cooper; John M Kaldor
HIV disease progression in Australia in the time of combination antiretroviral therapies.
The Medical journal of Australia 1998;169(9):469-72.
1998: A Carr; David A Cooper
Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor.
The New England journal of medicine 1998;339(18):1296.
1998: Andrew Carr; Sean Emery; A Lloyd; Jennifer Hoy; R Garsia; Martyn French; G Stewart; G Fyfe; David A Cooper
Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.
The Journal of infectious diseases 1998;178(4):992-9.
1998: Gilbert R Kaufmann; Chris Duncombe; Philip Cunningham; A Beveridge; Andrew Carr; David C Sayer; Martyn French; David A Cooper
Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals.
AIDS (London, England) 1998;12(13):1625-30.
1998: D Goldstein; P Hertzog; E Tomkinson; D Couldwell; S McCarville; S Parrish; P Cunningham; M Newell; M Owens; David A Cooper
Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification.
The Journal of infectious diseases 1998;178(3):858-61.
1998: Anthony D Kelleher; M Roggensack; Sean Emery; Andrew Carr; M A French; David A Cooper
Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens.
Clinical and experimental immunology 1998;113(1):85-91.
1998: Andrew Carr; Katherine Samaras; Donald J Chisholm; David A Cooper
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
Lancet 1998;351(9119):1881-3.
1998: Philippe Vanhems; J Lambert; David A Cooper; L Perrin; A Carr; Bernard Hirschel; Jeanette Vizzard; S Kinloch-de Loës; Robert Allard
Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(2):323-9.
1998: Anthony D Kelleher; M Roggensack; Angel Jaramillo; Don E Smith; A Walker; I Gow; M McMurchie; J Harris; G Patou; David A Cooper
Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
AIDS (London, England) 1998;12(2):175-82.
1998: Lesley J Ashton; Andrew Carr; Philip H Cunningham; M Roggensack; K McLean; Matthew Law; M Robertson; David A Cooper; John M Kaldor
Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group.
AIDS research and human retroviruses 1998;14(2):117-21.
1998: David A Cooper
Immunological effects of antiretroviral therapy.
Antiviral therapy 1998;3 Suppl 4():19-23.
1998: Praphan Phanuphak; David A Cooper; Joep M A Lange
Clinical trials in Asia.
AIDS (London, England) 1998;12 Suppl B():S163-7.
1997: Graeme J Stewart; Lesley J Ashton; Robyn Biti; Rosemary A Ffrench; Bruce Bennetts; N R Newcombe; Elizabeth M Benson; Andrew Carr; David A Cooper; John M Kaldor
Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.
AIDS (London, England) 1997;11(15):1833-8.
1997: Anna McNulty; M G Law; NJ Bodsworth; David A Cooper; John M Kaldor
Incidence of HIV infection in a cohort of homosexually active men.
Australian and New Zealand journal of public health 1997;21(6):587-9.
1997: Gregory J Dore; Jennifer Hoy; Simon Mallal; Yueming Li; Anne Mijch; Martyn A French; David A Cooper; John M Kaldor
Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;16(1):39-43.
1997: A Imrie; A Beveridge; W Genn; Jeanette Vizzard; David A Cooper
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
The Journal of infectious diseases 1997;175(6):1502-6.
1997: Philippe Vanhems; Robert Allard; David A Cooper; L Perrin; Jeanette Vizzard; Bernard Hirschel; S Kinloch-de Löes; A Carr; J Lambert
Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(5):965-70.
1997: Andrew E Grulich; John M Kaldor; Olympia Hendry; K Luo; NJ Bodsworth; David A Cooper
Risk of Kaposi's sarcoma and oroanal sexual contact.
American journal of epidemiology 1997;145(8):673-9.
1997: S V Thackway; V Furner; Anne Mijch; David A Cooper; D Holland; P Martinez; D Shaw; Ingrid van Beek; E Wright; K Clezy; John M Kaldor
Fertility and reproductive choice in women with HIV-1 infection.
AIDS (London, England) 1997;11(5):663-7.
1997: Menno D De Jong; STEFANO VELLA; Andrew Carr; Charles A B Boucher; A Imrie; Martyn French; Jennifer Hoy; S Sorice; S Pauluzzi; F Chiodo; Gerrit Jan Weverling; Marchina E Van Der Ende; P J Frissen; Hugo M Weigel; Robbert H Kauffmann; Joep M A Lange; R Yoon; M Moroni; E Hoenderdos; G Leitz; David A Cooper; D Hall; Peter Reiss
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
The Journal of infectious diseases 1997;175(4):966-70.
1997: Anthony D Kelleher; Sean Emery; Philip Cunningham; Chris Duncombe; Andrew Carr; H Golding; S Forde; J Hudson; M Roggensack; B D Forrest; David A Cooper
Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.
AIDS research and human retroviruses 1997;13(1):29-32.
1996: N N Zheng; L Hurren; B A Neilan; David A Cooper; S F Delaney; P W McQueen
Sequence analyses of the reverse transcriptase region of HIV type 1 isolates from Sydney, Australia.
AIDS research and human retroviruses 1996;12(18):1731-2.
1996: Andrew Carr; S Emery; Anthony D Kelleher; M Law; David A Cooper
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;13(4):320-6.
1996: Gregory J Dore; Yueming Li; Andrew E Grulich; Jennifer Hoy; Simon Mallal; Anne Mijch; Martyn A French; David A Cooper; John M Kaldor
Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort.
AIDS (London, England) 1996;10(12):1401-6.
1996: David A Cooper
The ascendancy--and the future--of combination antiretroviral and immunomodulatory therapies.
Journal of the International Association of Physicians in AIDS Care 1996;2(8):20-5.
1996: A Imrie; Andrew Carr; Chris Duncombe; R Finlayson; J Vizzard; M Law; J Kaldor; R Penny; David A Cooper
Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group.
The Journal of infectious diseases 1996;174(1):195-8.
1996: Matthew E Cramp; M C Hing; Deborah Marriott; J Freund; David A Cooper
Bile acid malabsorption in HIV infected patients with chronic diarrhoea.
Australian and New Zealand journal of medicine 1996;26(3):368-71.
1996: Andrew Carr; STEFANO VELLA; Menno D De Jong; F Sorice; A Imrie; Charles A B Boucher; David A Cooper
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
AIDS (London, England) 1996;10(6):635-41.
1996: D L Couldwell; Gregory J Dore; John Harkness; Deborah Marriott; David A Cooper; R Edwards; Yueming Li; John M Kaldor
Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room.
AIDS (London, England) 1996;10(5):521-5.
1996: N N Zheng; P W McQueen; L Hurren; L A Evans; M G Law; S Forde; S Barker; David A Cooper; S F Delaney
Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine.
The Journal of infectious diseases 1996;173(5):1092-6.
1996: David A Cooper
An interview with David A. Cooper, MD, DSc. Interview by Mark Mascolini.
Journal of the International Association of Physicians in AIDS Care 1996;2(3):17-22.
1996: David A Cooper
Australia's healthcare system.
Journal of the International Association of Physicians in AIDS Care 1996;2(3):14-6.
1996: Anthony D Kelleher; Andrew Carr; John J Zaunders; David A Cooper
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
The Journal of infectious diseases 1996;173(2):321-9.
1996: David A Cooper; T C Merigan
Clinical treatment.
AIDS (London, England) 1996;10 Suppl A():S133-4.
1996: Andrew Carr; David A Cooper
Current clinical experience with nevirapine for HIV infection.
Advances in experimental medicine and biology 1996;394():299-304.
1995: O Distler; P W McQueen; M L Tsang; L A Evans; L Hurren; C Byrne; R Penny; David A Cooper; S F Delaney
Primary structure of the V3 region of gp120 from sequential human immunodeficiency virus type 1 isolates obtained from patients from the time of seroconversion.
The Journal of infectious diseases 1995;172(5):1384-7.
1995: S Emery; David A Cooper
Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.
Australian and New Zealand journal of medicine 1995;25(4):344-9.
1995: John J Zaunders; Andrew Carr; L McNally; R Penny; David A Cooper
Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes.
AIDS (London, England) 1995;9(6):561-6.
1995: A M McNulty; J M Kaldor; David A Cooper
Change in zidovudine prescribing practices in Australia, 1991-1993.
Australian and New Zealand journal of medicine 1995;25(3):239-40.
1995: Jacques Corbeil; L A Evans; P W McQueen; E Vasak; P D Edward; Douglas D Richman; R Penny; David A Cooper
Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1.
Immunology and cell biology 1995;73(2):140-5.
1995: O Distler; P W McQueen; M L Tsang; C Byrne; B A Neilan; L Evans; R Penny; David A Cooper; S F Delaney
Characterization of the V3 region of HIV-1 isolates from Sydney, Australia.
AIDS research and human retroviruses 1995;11(3):423-5.
1995: K Luo; M Law; John M Kaldor; A M McDonald; David A Cooper
The role of initial AIDS-defining illness in survival following AIDS.
AIDS (London, England) 1995;9(1):57-63.
1995: Andrew Carr; David A Cooper
Pathogenesis and management of HIV-associated drug hypersensitivity.
AIDS clinical review 1995;():65-97.
1994: A C Grunseit; M Perdices; N Dunbar; David A Cooper
Neuropsychological function in asymptomatic HIV-1 infection: methodological issues.
Journal of clinical and experimental neuropsychology 1994;16(6):898-910.
1994: B Tindall; S Forde; M W Ross; D Goldstein; S Barker; David A Cooper
Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine.
Patient education and counseling 1994;24(3):261-6.
1994: M L Tsang; L A Evans; P McQueen; L Hurren; C Byrne; R Penny; B Tindall; David A Cooper
Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
The Journal of infectious diseases 1994;170(5):1141-7.
1994: David A Cooper
HIV therapy advances. Early antiretroviral therapy.
AIDS (London, England) 1994;8 Suppl 3():S9-14.
1994: Andrew Carr; E Vasak; V Munro; R Penny; David A Cooper
Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection.
Clinical and experimental immunology 1994;97(2):260-5.
1994: C E Swanson; B Tindall; David A Cooper
Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group.
AIDS (London, England) 1994;8(5):625-34.
1994: Andrew Carr; Annette Gross; Janelle Hoskins; R Penny; David A Cooper
Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients.
AIDS (London, England) 1994;8(3):333-7.
1994: B Tindall; S Forde; D Goldstein; M W Ross; David A Cooper
Sexual dysfunction in advanced HIV disease.
AIDS care 1994;6(1):105-7.
1994: K Clezy; Thira Sirisanthana; V Sirisanthana; Bruce J Brew; David A Cooper
Late manifestations of HIV in Asia and the Pacific.
AIDS (London, England) 1994;8 Suppl 2():S35-43.
1993: Andrew Carr; B Tindall; R Penny; David A Cooper
In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV.
Clinical and experimental immunology 1993;94(1):21-5.
1993: John M Kaldor; B Tindall; P Williamson; J Elford; David A Cooper
Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men.
Journal of acquired immune deficiency syndromes 1993;6(10):1145-9.
1993: Andrew Carr; M Loewenthal; David A Cooper
Update on reverse transcriptase inhibitors in HIV disease.
Israel journal of medical sciences 1993;29(10 Suppl):26-30.
1993: B Tindall; S Forde; A Carr; S Barker; David A Cooper
Attitudes to euthanasia and assisted suicide in a group of homosexual men with advanced HIV disease.
Journal of acquired immune deficiency syndromes 1993;6(9):1069-70.
1993: B Tindall; J Elford; T Sharkey; A Carr; J Kaldor; David A Cooper
CD4+ lymphocytopenia in HIV-seronegative homosexual men.
AIDS (London, England) 1993;7(9):1272-3.
1993: David A Cooper; J M Gatell; S Kroon; N Clumeck; J Millard; F D Goebel; Johan Bruun; G Stingl; R L Melville; J González-Lahoz
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
The New England journal of medicine 1993;329(5):297-303.
1993: S J Bell; A F Geczy; G J Russell-Jones; S Croft; David A Cooper; R Penny
Augmentation of HIV-specific lymphoproliferation in HIV-infected individuals by TraT: a novel T-cell immunopotentiating agent.
AIDS (London, England) 1993;7(6):807-12.
1993: M J Boyle; Tom Sculley; R Penny; William A Sewell; M Tschuchnigg; M F Berger; David A Cooper
The role of Epstein-Barr virus subtypes in human immunodeficiency virus-associated lymphoma.
Leukemia & lymphoma 1993;10(1-2):17-23.
1993: M J Boyle; M F Berger; M Tschuchnigg; J E Valentine; B G Kennedy; M Divjak; David A Cooper; J J Turner; R Penny; William A Sewell
Increased expression of interferon-gamma in hyperplastic lymph nodes from HIV-infected patients.
Clinical and experimental immunology 1993;92(1):100-5.
1993: A Carr; R Penny; David A Cooper
Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS).
The Journal of allergy and clinical immunology 1993;91(2):683-5.
1993: David A Cooper; P O Pehrson; C Pedersen; M Moroni; E Oksenhendler; W Rozenbaum; N Clumeck; V Faber; W Stille; B Hirschel
The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
AIDS (London, England) 1993;7(2):197-207.
1993: M J Boyle; E Vasak; M Tschuchnigg; J J Turner; Tom Sculley; R Penny; David A Cooper; B Tindall; William A Sewell
Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise.
Blood 1993;81(2):468-74.
1993: M J Boyle; M McMurchie; B Tindall; David A Cooper
HIV seroconversion illness.
The Medical journal of Australia 1993;158(1):42-4.
1993: Andrew Carr; R Penny; David A Cooper
Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.
AIDS (London, England) 1993;7(1):65-71.
1993: D Goldstein; David A Cooper
Current status of clinical trials in HIV disease in Australia.
Journal of acquired immune deficiency syndromes 1993;6 Suppl 1():S68-71.
1993: A Carr; R Penny; David A Cooper
Prophylaxis of opportunistic infections in patients with HIV infection.
Journal of acquired immune deficiency syndromes 1993;6 Suppl 1():S56-60.
1993: M J Boyle; William A Sewell; S T Milliken; David A Cooper; R Penny
HIV and malignancy.
Journal of acquired immune deficiency syndromes 1993;6 Suppl 1():S5-9.
1993: Andrew Carr; C Swanson; R Penny; David A Cooper
Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS.
The Journal of infectious diseases 1993;167(1):180-5.
1992: M Perdices; N Dunbar; A Grunseit; W Hall; David A Cooper
Anxiety, depression and HIV related symptomatology across the spectrum of HIV disease.
The Australian and New Zealand journal of psychiatry 1992;26(4):560-6.
1992: M T Kyaw; L Hurren; L Evans; D J Moss; David A Cooper; E Benson; D Esmore; Tom Sculley
Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients.
AIDS research and human retroviruses 1992;8(11):1869-74.
1992: Jennifer C Learmont; B Tindall; L Evans; A Cunningham; P Cunningham; J Wells; R Penny; J Kaldor; David A Cooper
Long-term symptomless HIV-1 infection in recipients of blood products from a single donor.
Lancet 1992;340(8824):863-7.
1992: S J Bell; David A Cooper; B E Kemp; R R Doherty; R Penny
Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI).
Clinical and experimental immunology 1992;90(1):6-12.
1992: S J Bell; David A Cooper; B E Kemp; R R Doherty; R Penny
CD8+ T-cells from HIV-infected patients can either augment or abrogate HIV-specific lymphoproliferation.
Clinical immunology and immunopathology 1992;64(3):254-60.
1992: B Tindall; L Evans; P Cunningham; P McQueen; L Hurren; E Vasak; J Mooney; David A Cooper
Identification of HIV-1 in semen following primary HIV-1 infection.
AIDS (London, England) 1992;6(9):949-52.
1992: B Tindall; T Sharkey; J Kaldor; David A Cooper
Effect of the revised CDC case definition of AIDS on the number of AIDS cases in the Sydney AIDS Prospective Study.
Australian and New Zealand journal of medicine 1992;22(4):369-73.
1992: A Carr; B Tindall; B J Brew; Deborah Marriott; John Harkness; R Penny; David A Cooper
Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS.
Annals of internal medicine 1992;117(2):106-11.
1992: N Dunbar; M Perdices; A Grunseit; David A Cooper
Changes in neuropsychological performance of AIDS-related complex patients who progress to AIDS.
AIDS (London, England) 1992;6(7):691-700.
1992: M J Boyle; Tom Sculley; David A Cooper; J J Turner; R Penny; William A Sewell
Epstein-Barr virus and HIV play no direct role in persistent generalized lymphadenopathy syndrome.
Clinical and experimental immunology 1992;87(3):357-61.
1992: Andrew Carr; B Tindall; R Penny; David A Cooper
Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
AIDS (London, England) 1992;6(2):165-71.
1992: S J Bell; David A Cooper; B E Kemp; R R Doherty; R Penny
Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1.
Clinical and experimental immunology 1992;87(1):37-45.
1991: M J Boyle; William A Sewell; Tom Sculley; A Apolloni; J J Turner; C E Swanson; R Penny; David A Cooper
Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma.
Blood 1991;78(11):3004-11.
1991: David A Cooper; C Pedersen; Fernando Aiuti; J L Vilde; M Ruhnke; P O Pehrson; N Clumeck; C Farthing; R Lüthy; R R Doherty
The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group.
AIDS (London, England) 1991;5(8):933-43.
1991: Jacques Corbeil; L A Evans; E Vasak; David A Cooper; R Penny
Culture and properties of cells derived from Kaposi sarcoma.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(9):2972-6.
1991: B Tindall; H Gaines; A Imrie; M A von Sydow; L Evans; O Strannegard; M L Tsang; S Lindback; David A Cooper
Zidovudine in the management of primary HIV-1 infection.
AIDS (London, England) 1991;5(5):477-84.
1991: M Tenant-Flowers; M J Boyle; D Carey; Deborah Marriott; John Harkness; R Penny; David A Cooper
Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis.
AIDS (London, England) 1991;5(3):311-5.
1991: A Carr; David A Cooper; R Penny
Allergic manifestations of human immunodeficiency virus (HIV) infection.
Journal of clinical immunology 1991;11(2):55-64.
1991: Joep M A Lange; David A Cooper; Sven A Danner
Antiretroviral treatment: state of the art and future directions.
AIDS (London, England) 1991;5 Suppl 2():S181-8.
1990: M J Boyle; C E Swanson; J J Turner; I L Thompson; J Roberts; R Penny; David A Cooper
Definition of two distinct types of AIDS-associated non-Hodgkin lymphoma.
British journal of haematology 1990;76(4):506-12.
1990: M L McLaws; A R Brown; Philip H Cunningham; A A Imrie; B Wilcken; David A Cooper
Prevalence of maternal HIV infection based on anonymous testing of neonates, Sydney 1989.
The Medical journal of Australia 1990;153(7):383-6.
1990: B Tindall; C E Swanson; David A Cooper
Development of AIDS in a cohort of HIV-seropositive homosexual men in Australia.
The Medical journal of Australia 1990;153(5):260-5.
1990: Tom Sculley; A Apolloni; L Hurren; Denis Moss; David A Cooper
Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects.
The Journal of infectious diseases 1990;162(3):643-8.
1990: C E Swanson; David A Cooper
Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. The Australian Zidovudine Study Group.
AIDS (London, England) 1990;4(8):749-57.
1990: Ann M McDonald; B M Whyte; D Jacobs; C R Philpot; D L Bradford; B Monheit; M L James; T Goulden; David A Cooper; John M Kaldor
Voluntary HIV antibody testing among STD clinic patients: a pilot study.
The Medical journal of Australia 1990;153(1):12-4.
1990: B Tindall; R Cotton; C Swanson; M Perdices; NJ Bodsworth; A Imrie; David A Cooper
Fifth International Conference on the acquired immunodeficiency syndrome.
The Medical journal of Australia 1990;152(4):204-11, 214.
1990: NJ Bodsworth; David A Cooper
Ribavirin: a role in HIV infection?
Journal of acquired immune deficiency syndromes 1990;3(9):893-5.
1990: M Perdices; David A Cooper
Neuropsychological investigation of patients with AIDS and ARC.
Journal of acquired immune deficiency syndromes 1990;3(6):555-64.
1989: B J Brew; M Perdices; P Darveniza; P Edwards; B Whyte; W J Burke; R Garrick; D O'Sullivan; R Penny; David A Cooper
The neurological features of early and 'latent' human immunodeficiency virus infection.
Australian and New Zealand journal of medicine 1989;19(6):700-5.
1989: B Tindall; M Hing; P Edwards; T Barnes; A Mackie; David A Cooper
Severe clinical manifestations of primary HIV infection.
AIDS (London, England) 1989;3(11):747-9.
1989: B Tindall; C Swanson; Basil Donovan; David A Cooper
Sexual practices and condom usage in a cohort of homosexual men in relation to human immunodeficiency virus status.
The Medical journal of Australia 1989;151(6):318-22.
1989: Tom Sculley; A Apolloni; R Stumm; Denis Moss; N Mueller-Lantczh; Ihor Misko; David A Cooper
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus.
Virology 1989;171(2):401-8.
1989: M Perdices; David A Cooper
Simple and choice reaction time in patients with human immunodeficiency virus infection.
Annals of neurology 1989;25(5):460-7.
1989: B Tindall; R Finlayson; K Mutimer; F A Billson; V F Munro; David A Cooper
Malignant melanoma associated with human immunodeficiency virus infection in three homosexual men.
Journal of the American Academy of Dermatology 1989;20(4):587-91.
1989: B Tindall; C Swanson; B M Whyte; M Perdices; David A Cooper
Fourth International Conference on the acquired immunodeficiency syndrome.
The Medical journal of Australia 1989;150(2):87-92.
1988: David A Cooper; Deborah Marriott; J L Harkness; D H Bryant
The acquired immunodeficiency syndrome and tuberculosis.
The Medical journal of Australia 1988;149(11-12):714-5.
1988: B M Whyte; David A Cooper
The surveillance definition of the acquired immunodeficiency syndrome and the clinical classification of infection with the human immunodeficiency virus type 1.
The Medical journal of Australia 1988;149(7):368-73.
1988: Tom Sculley; S M Cross; P Borrow; David A Cooper
Prevalence of antibodies to Epstein-Barr virus nuclear antigen 2B in persons infected with the human immunodeficiency virus.
The Journal of infectious diseases 1988;158(1):186-92.
1988: B Tindall; David A Cooper; B Donovan; R Penny
Primary human immunodeficiency virus infection. Clinical and serologic aspects.
Infectious disease clinics of North America 1988;2(2):329-41.
1988: David A Cooper; B Tindall; E J Wilson; A A Imrie; R Penny
Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus.
The Journal of infectious diseases 1988;157(5):889-96.
1988: B Tindall; David A Cooper; Basil Donovan; T Barnes; C R Philpot; J Gold; R Penny
The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men.
Australian and New Zealand journal of medicine 1988;18(1):8-15.
1985: David A Cooper; J Gold; P Maclean; Basil Donovan; R Finlayson; T G Barnes; H M Michelmore; P Brooke; R Penny
Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion.
Lancet 1985;1(8428):537-40.